Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Dodd

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Opinion in Urology|October 14, 2006
New chemotherapy regimens for metastatic bladder cancerP M Dodd, D F Bajorin
The Urologic Clinics of North America|September 5, 1998
Poor-risk germ cell tumors. Recent developmentsP M Dodd, R J Motzer, D F Bajorin
Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.
Cancer|March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.
Cancer Investigation|October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancerP M Dodd, J A McCaffrey, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tractP M Dodd, J A McCaffrey, S Hilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, H Herr, et al.
The Surgical Technologist|June 9, 1986
HHS circulating regulations finalized on June 17H M Blackford, N A Davis, P M Dodd, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Opinion in Urology|October 14, 2006
New chemotherapy regimens for metastatic bladder cancerP M Dodd, D F Bajorin
The Urologic Clinics of North America|September 5, 1998
Poor-risk germ cell tumors. Recent developmentsP M Dodd, R J Motzer, D F Bajorin
Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.
Cancer|March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.
Cancer Investigation|October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancerP M Dodd, J A McCaffrey, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tractP M Dodd, J A McCaffrey, S Hilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, H Herr, et al.
The Surgical Technologist|June 9, 1986
HHS circulating regulations finalized on June 17H M Blackford, N A Davis, P M Dodd, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Pageof 1